Tsai, G; Coyle, JT (1998). The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annual Review of Medicine. 49: 173–84. doi:10.1146/annurev.med.49.1.173. PMID9509257.
De Witte, P; Littleton, J; Parot, P; Koob, G (2005). Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs (англ.). 19 (6): 517–37. doi:10.2165/00023210-200519060-00004. PMID15963001.
Al Qatari, M; Khan, S; Harris, B; Littleton, J (2001). Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcoholism: Clinical and Experimental Research (англ.). 25 (9): 1276–83. doi:10.1111/j.1530-0277.2001.tb02348.x. PMID11584146.
Acamprosate(англ.). DrugBank. University of Alberta (19 ноября 2017). — «Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. […] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification, unlike naltrexone and disulfiram.» Дата обращения: 30 декабря 2023. Архивировано 7 августа 2023 года.
Acamprosate: Biological activity (неопр.). IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. — «Due to the complex nature of this drug's MMOA, and a paucity of well defined target affinity data, we do not map to a primary drug target in this instance.» Дата обращения: 21 мая 2021. Архивировано 1 декабря 2017 года.
Acamprosate: Summary(англ.). IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. — «Acamprosate is a NMDA glutamate receptor antagonist and a positive allosteric modulator of GABAA receptors. Marketed formulations contain acamprosate calcium». Дата обращения: 21 мая 2021. Архивировано 1 декабря 2017 года.
Mason, BJ (2001). Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. The Journal of Clinical Psychiatry (англ.). 62 Suppl 20: 42–8. PMID11584875.
Tsai, G; Coyle, JT (1998). The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annual Review of Medicine. 49: 173–84. doi:10.1146/annurev.med.49.1.173. PMID9509257.
De Witte, P; Littleton, J; Parot, P; Koob, G (2005). Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs (англ.). 19 (6): 517–37. doi:10.2165/00023210-200519060-00004. PMID15963001.
Al Qatari, M; Khan, S; Harris, B; Littleton, J (2001). Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcoholism: Clinical and Experimental Research (англ.). 25 (9): 1276–83. doi:10.1111/j.1530-0277.2001.tb02348.x. PMID11584146.
Acamprosate: Biological activity (неопр.). IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. — «Due to the complex nature of this drug's MMOA, and a paucity of well defined target affinity data, we do not map to a primary drug target in this instance.» Дата обращения: 21 мая 2021. Архивировано 1 декабря 2017 года.
Acamprosate: Summary(англ.). IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. — «Acamprosate is a NMDA glutamate receptor antagonist and a positive allosteric modulator of GABAA receptors. Marketed formulations contain acamprosate calcium». Дата обращения: 21 мая 2021. Архивировано 1 декабря 2017 года.
Acamprosate(англ.). DrugBank. University of Alberta (19 ноября 2017). — «Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. […] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification, unlike naltrexone and disulfiram.» Дата обращения: 30 декабря 2023. Архивировано 7 августа 2023 года.